Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 12 - 21 tags : Treatment save search
Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma
Published: 2022-12-21 (Crawled : 22:00) - investors.phiopharma.com
PHIO | $0.631 -1.07% -1.08% 29K
|
Health Technology
|
| O: 9.33%
H: 0.0%
C: -12.49%
ph-762 treatment pharmaceuticals program study cell carcinoma
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2022-12-21 (Crawled : 14:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: -1.52%
H: 0.18%
C: -3.85%
treatment leukemia trial approval acute myeloid leukemia aml phase 1
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
Published: 2022-12-21 (Crawled : 13:20) - biospace.com/
IFRX | $1.36 7.94% 7.35% 140K
|
Health Technology
|
| O: 10.9%
H: 17.09%
C: 15.38%
covid-19 treatment agreement china
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Published: 2022-12-21 (Crawled : 13:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 6.05%
H: 2.65%
C: 0.66%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -0.05%
H: 2.34%
C: 1.64%
treatment application diabetes
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
Published: 2022-12-21 (Crawled : 13:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.35%
H: 0.99%
C: 0.92%
lynparza treatment approved cancer prostate cancer
AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine
Published: 2022-12-21 (Crawled : 13:00) - biospace.com/
PMGM 4 | $11.21 0.09% 1
|
| Email alert
Add to watchlist
AEON | $4.66 -28.75% 2.58% 110K
|
| Email alert
Add to watchlist
abp-450 treatment biopharma trial migraine phase 2
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Published: 2022-12-21 (Crawled : 12:20) - biospace.com/
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -5.08%
H: 5.66%
C: 3.35%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -2.9%
H: 3.1%
C: 2.91%
cd20 duobody treatment drug japan application submission
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
Published: 2022-12-21 (Crawled : 12:20) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: 0.82%
H: 6.99%
C: 5.37%
treatment drug application therapeutics food vitreoretinal lymphoma
Zynlonta® (loncastuximab tesirine) approved in the EU for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Published: 2022-12-21 (Crawled : 09:00) - prnewswire.com
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 14.15%
H: 1.93%
C: -16.25%
zynlonta treatment approved
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Published: 2022-12-21 (Crawled : 09:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 14.15%
H: 1.93%
C: -16.25%
zynlonta treatment approval therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.